AVENUE THERAPEUTICS, INC.
ATXI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ATXI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ATXI
Avenue Therapeutics, Inc. (ATXI) is a clinical-stage biopharmaceutical company with no approved drug products, focused on developing and seeking regulatory approval for its product candidates, currently holding $1.9M in cash as of 2026-06-30.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for AVENUE THERAPEUTICS, INC..
Similar companies
Avenue Therapeutics, Inc. (ATXI) is a clinical-stage biopharmaceutical company with no approved drug products, focused on developing and seeking regulatory approval for its product candidates, currently holding $1.9M in cash as of 2026-06-30.
- No drug products for sale; success depends on regulatory approval and commercialization of product candidates [sec · filed 2025-11-12].
- Cash and cash equivalents of $1.9M as of 2026-06-30 [sec].
- Net income of -$0.7M for the period ended 2026-06-30 [sec].
- Research and development expenses decreased to $0.8M for the nine months ended September 30, 2025, from $6.1M in the prior year period, primarily due to reduced development costs for AJ201 [sec_mda · as of 2025-11-13].
- General and administrative expenses were $1.0M for the six months ended June 30, 2026, down from $2.4M in the same period of 2025 [sec_mda · as of 2026-08-07].
What works
- The company has reduced operating expenses, with general and administrative expenses decreasing by $1.4M for the six months ended June 30, 2026 compared to the prior year period [sec_mda · as of 2026-08-07].
- Research and development expenses have been significantly reduced, from $6.1M to $0.8M for the nine months ended September 30, 2025, reflecting a strategic shift in development focus [sec_mda · as of 2025-11-13].
What to weigh
- The company currently has no drug products for sale and its success is entirely dependent on product candidates receiving regulatory approval and being successfully commercialized [sec · filed 2025-11-12].
- Cash and cash equivalents are only $1.9M as of 2026-06-30, which may limit the company's ability to fund operations and development activities for an extended period [sec].
- The company has a history of net losses, with a net loss of $0.7M for the period ended 2026-06-30 [sec].
- There is a dispute with the licensor of AJ201 regarding an attempted license agreement termination, adding legal and operational uncertainty [sec_mda · as of 2025-03-31].
From the filings
Quoted directly from source documents.
Company has no approved drug products and depends on regulatory approval.
“the fact that we currently have no drug products for sale and that our success is dependent on our product candidates receiving regulatory approval and being successfully commercialized”
SEC filings · November 12, 2025
Dispute with AJ201 licensor.
“the purported termination letter from, and dispute with, the licensor of AJ201 regarding their attempted license agreement termination”
SEC MD&A · March 31, 2025
Catalyst timeline
- 2025-08-20 · Phase 2 Start: A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics — The study is recruiting and will evaluate the occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1).
Risks & what to watch (4)›
Key risks
- No approved products — Company has no drug products for sale; success hinges on regulatory approval and commercialization of candidates [sec · filed 2025-11-12].
- Limited cash runway — Cash of $1.9M as of 2026-06-30 may be insufficient to sustain operations and development for long [sec].
- AJ201 license dispute — Dispute with AJ201 licensor over attempted termination adds legal and operational uncertainty [sec_mda · as of 2025-03-31].
- History of net losses — Company reported a net loss of $0.7M for the period ended 2026-06-30, indicating ongoing unprofitability [sec].
What to watch
- Progress of the Phase 1/2 first-in-human study (NCT06998407) for the company's product candidate, which began recruiting in August 2025 [catalyst].
- Updates on the dispute with the AJ201 licensor and any impact on the company's pipeline or financials [sec_mda · as of 2025-03-31].
- Cash burn rate and any future financing activities given the low cash balance of $1.9M as of 2026-06-30 [sec].
- Regulatory interactions and any submissions for the remaining product candidate [sec_mda · as of 2026-08-07].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run AVENUE THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AVENUE THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
12.3 months
D/E 2.47
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2024Institutional holders
6
Total value held
$99K
| Holder | Shares | Value |
|---|---|---|
| boothbay fund management, llc | 41,089 | $82K |
| ubs group ag | 7,920 | $16K |
| wells fargo & company/mn | 500 | $1K |
| bank of america corp /de/ | 14 | $28 |
| sbi securities co., ltd. | 9 | $18 |
| concourse financial group securities, inc. | 0 | $0 |
Short Interest
as of May 20, 2026- % of float
- 2.8%
- Days to cover
- 0.7
- Shares short
- 59,696
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ATXI short interestGovernance
Frequently asked questions
What is the AI investment thesis for AVENUE THERAPEUTICS, INC.?
Avenue Therapeutics, Inc. (ATXI) is a clinical-stage biopharmaceutical company with no approved drug products, focused on developing and seeking regulatory approval for its product candidates, currently holding $1.9M in cash as of 2026-06-30.
What is AVENUE THERAPEUTICS, INC.'s lead drug candidate?
AVENUE THERAPEUTICS, INC.'s most advanced tracked candidate is atx-04 (Preclinical) for Pompe disease.
Who is the CEO of AVENUE THERAPEUTICS, INC.?
Dr. Alexandra MacLean M.D. is the chief executive officer of AVENUE THERAPEUTICS, INC. (ATXI).
Where is AVENUE THERAPEUTICS, INC. headquartered?
AVENUE THERAPEUTICS, INC. (ATXI) is headquartered in Bay Harbor Islands, FL, United States.
What therapeutic areas does AVENUE THERAPEUTICS, INC. focus on?
AVENUE THERAPEUTICS, INC. develops therapies across Rare Disease, Neurology, Cardiovascular, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.